The Dream Team

Curated intelligence dossiers on leaders who can actually help discover longevity therapeutics. Not influencers. Not commentators. People building the science and the companies.

longevity therapeutics drug discovery epigenetic reprogramming clinical translation senolytics NAD+ biology AI drug discovery

Automation & Tools

πŸ€– Automated Actions

Generate PDFs, send reports, and sync with Substack β€” all automated.

Dream Team Profiles

Each profile is a complete intelligence card β€” like a football trading card for longevity science. Criteria: must have direct therapeutic impact potential.

David Sinclair

David A. Sinclair

Professor of Genetics
Harvard Medical School Β· πŸ‡ΊπŸ‡Έ/πŸ‡¦πŸ‡Ί
8.5
Overall
πŸ”— LinkedIn πŸ“š Scholar 𝕏 Twitter πŸ§ͺ Lab
152
h-index
130K+
Citations
250+
Papers
200+
Patents
Therapeutic Impact
8
Scientific Rigor
7
Translation Track
9
Industry Influence
10

Key Capabilities

Epigenetic Reprogramming Sirtuin Biology NAD+ Metabolism Gene Therapy Biomarker Development Small Molecule Discovery Science Communication

Companies & Ventures

Life Biosciences
Co-founder
Epigenetic reprogramming gene therapies
Phase 1 (2026)
MetroBiotech
Co-founder
NAD+ therapeutics (MIB-626)
Active
InsideTracker
Co-founder & SAB
Biomarker health optimization
Active
Galilei Biosciences
Co-founder
SIRT6 activators
Active
Senolytic Therapeutics
Co-founder
Senolytic drugs
Life Bio subsidiary
Animal Bioscience
Co-founder
Pet longevity
Active

Key Therapeutic Contributions

  • Discovered resveratrol activates SIRT1 (Nature 2003) β€” launched sirtuin field
  • Information Theory of Aging β€” aging as recoverable epigenetic information loss
  • ICE mouse model proving epigenetic causality of aging
  • Partial epigenetic reprogramming reverses aging in vivo
  • NAD+ precursor clinical programs (MIB-626 Phase I/II)
  • Epigenetic age reversal gene therapy β€” FDA Phase 1 for glaucoma/NAION (2026)
  • >200 patents in aging therapeutics
The most publicly recognized longevity scientist alive. Sinclair's core thesis β€” that aging is a recoverable loss of epigenetic information β€” has generated enormous scientific and commercial output. His NAD+ and sirtuin work created an entire supplement industry, while Life Biosciences is now the first company testing partial epigenetic reprogramming in human eyes (FDA Phase 1, 2026). Controversies exist (the 2023 Nature retraction of some reprogramming claims), but his lab's revised approach continues advancing. Unmatched in translating aging biology into funded ventures and public discourse.

⚠️ Notable Controversies

  • 2023 Nature retraction of key reprogramming paper (data integrity concerns)
  • Supplement industry conflicts of interest allegations
  • Resveratrol clinical efficacy debates (GSK/SRT program failed)

Substack Connection

πŸ”— Connect Your Substack

Link your Substack publication to automatically pull aging research collections and publish Dream Team profiles.

Status: Not connected β€” provide your Substack URL to enable auto-publishing and collection sync.

Aging Research Collections (Substack)

Curated research collections from aging-focused Substacks. Auto-updated when connected.

🧬 Epigenetic Reprogramming

12 posts Β· Updated weekly

Yamanaka factors, partial reprogramming, age reversal in vivo

πŸ’Š Senolytic Therapeutics

8 posts Β· Updated monthly

Dasatinib+Quercetin, fisetin, navitoclax, clinical trials

πŸ§ͺ NAD+ & Sirtuins

15 posts Β· Updated weekly

NMN, NR, SIRT1-7, clinical data, metabolomics

πŸ€– AI for Drug Discovery

20 posts Β· Updated weekly

Insilico Medicine, AlphaFold, generative chemistry, clinical AI

⏱️ Biological Clocks

10 posts Β· Updated monthly

Horvath clocks, DunedinPACE, GrimAge, transcriptomic aging

πŸ₯ Clinical Trials in Aging

6 posts Β· Updated monthly

TAME trial, rapamycin, metformin, GLP-1 agonists, geroscience

Nominate a Leader

Submit nominations for the Dream Team. Criteria: must have direct potential to help discover longevity therapeutics. No influencers, no commentators β€” scientists and builders only.

πŸ“‹ Submission Form

Methodology

Inclusion criteria: Must have direct, demonstrable impact on longevity therapeutic discovery. This means:

  • Active drug discovery programs (preclinical or clinical)
  • Novel targets or mechanisms validated in vivo
  • Platform technologies enabling therapeutic development
  • Biomarkers/clocks enabling clinical endpoints
  • Companies with funded pipelines targeting aging

Scoring (1-10 per dimension):

  • Therapeutic Impact β€” drugs in clinic, targets validated, lives impacted
  • Scientific Rigor β€” reproducibility, peer review, retractions
  • Translational Track β€” bench-to-bedside success, IP portfolio
  • Industry Influence β€” companies founded, capital raised, partnerships